Lumira Ventures

Founded in Toronto in 2007, Lumira Ventures is a venture capital firm focusing on investments in biotechnology, biopharmaceuticals, medical devices, digital health, and consumer health companies. With offices across North America, the firm invests primarily in Canada and the United States, typically allocating between USD 5 million to USD 15 million per investment. Lumira Ventures actively supports its portfolio companies by facilitating access to funding sources, partners, and market opportunities.

Baye Galligan

Director of Research

Daniel Hétu MD

Managing Director

Jacki Jenuth Ph.D

Partner and COO

Vasco Larcina

CFO

Alice Luo

Analyst

David Novak

Venture Partner

Suman Rao

Senior Associate

Benjamin Rovinski Ph.D

Managing Director

Nikhil Thatte

Partner

Peter van der Velden

Founder and Managing General Partner

Past deals in Quebec

Puzzle Medical Devices

Series A in 2025
Puzzle Medical Devices develops innovative heart pump solutions to treat advanced heart failure. Its flagship product, ModulHeart, is a modular percutaneous device designed to reduce cardiac afterload and improve renal perfusion. The device's unique design enables safe percutaneous implantation, supporting both renal and cardiac function with low risk of complications. Puzzle Medical has successfully completed its first-in-human study, demonstrating improvements in cardiac and kidney function.

Axonis Therapeutics

Series A in 2024
Axonis Therapeutics is a biotechnology company focused on neurological disorders. It develops medicines targeting KCC2, a critical mediator of inhibition within the brain, using a proprietary neuron-specific K-Cl cotransporter (KCC2) discovery engine. The company aims to improve lives by treating conditions such as epilepsy and pain.

Gladius Pharmaceuticals

Venture Round in 2018
Gladius Pharmaceuticals Inc. is a biotechnology firm based in Montréal that focuses on developing innovative antibiotics to address life-threatening, multi-drug-resistant bacterial infections. The company is dedicated to creating novel drug candidates that demonstrate broad-spectrum efficacy against gram-negative pathogens. Gladius's antibiotics aim to assist in the empiric treatment of these infections and have the potential to replace older generation cephalosporins, thereby providing physicians with effective treatment options for challenging bacterial infections.

Opsens

Post in 2016
Opsens Inc. is a Canadian company that specializes in developing, manufacturing, and selling fiber optic sensors for various applications, primarily in interventional cardiology and industrial markets. It operates in two main segments: Medical and Industrial. The Medical segment focuses on physiological measurements, including Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR), and offers products such as the OptoWire, an advanced optical pressure guidewire, and miniature optical sensors for pressure and temperature measurement. These sensors are designed for integration into medical devices, catering to needs in areas like transcatheter aortic valve replacement. The Industrial segment provides fiber optic sensing solutions for diverse applications, including life sciences, energy, and civil engineering. Opsens markets its products through a direct sales force and distributors across the United States, Japan, Canada, and internationally, with its headquarters located in Québec, Canada.

Gladius Pharmaceuticals

Series A in 2015
Gladius Pharmaceuticals Inc. is a biotechnology firm based in Montréal that focuses on developing innovative antibiotics to address life-threatening, multi-drug-resistant bacterial infections. The company is dedicated to creating novel drug candidates that demonstrate broad-spectrum efficacy against gram-negative pathogens. Gladius's antibiotics aim to assist in the empiric treatment of these infections and have the potential to replace older generation cephalosporins, thereby providing physicians with effective treatment options for challenging bacterial infections.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.